Omnia Korani: Prioritizing long-term, robust evidence in treatment decisions
Omnia Korani, Haematology and Bone Transplant Specialist at Air Force Specialized Hospital, shared a post on LinkedIn:
“In the evolving landscape of oncology, where new data and FDA approvals arrive rapidly, it’s essential to remember that while strong evidence is necessary to implement effective cancer therapies, even more compelling data is needed to discontinue one.
Many treatments showing promise in disease-free survival (DFS) often lose their significance with longer follow-up, and the scarcity of head-to-head and non-inferiority trials limits our ability to make accurate comparisons.
It’s a reminder that we must maintain a critical lens and prioritize long-term, robust evidence when making treatment decisions.”
More posts featuring Omnia Korani.
Omnia Korani is a Hematology and Bone Transplant Specialist at the Air Force Specialized Hospital, a Breast Cancer Specialist at Baheya Charity Women’s Cancer Hospital, and an Assistant Lecturer at the National Cancer Institute.
She is a medical oncologist with expertise in breast and gynecological cancers, hematological malignancies, and bone marrow transplantation (BMT).
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023